AVGR Avinger Inc

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Avinger, Inc.

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky, LLP announces it has commenced an investigation of Avinger, Inc. (“Avinger”) (NASDAQ:AVGR) concerning possible violations of federal securities laws.

On January 30, 2015, Avinger held its Initial Public Offering at $13 per share. On July 12, 2016, the Company announced its second quarter revenue and lowered its sales guidance for 2016 from $25-30 million to $19-23 million, due in part to lower than anticipated sales of the Company’s Pantheris device. Then on May 3, 2017 the stock closed at $0.57 per share, a decline of over 95% from the Initial Public Offering price. To obtain additional information, go to:

http://zlk.9nl.com/avinger

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
11/05/2017

Underlying

AVGRAvinger Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Avinger Inc

 PRESS RELEASE
Free
AVGR AVINGER INC

Avinger Reports Third Quarter 2019 Financial Results

Avinger Reports Third Quarter 2019 Financial Results Increased Utilization Drives 33% Growth in Catheter Sales and Gross Margin ExpansionTotal Pantheris Revenue Increases 81% Year-over-Year REDWOOD CITY, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported results for the quarter ended September 30, 2019. Third Quarter Highlights Increased revenue 19% year-...

November 5, 2019 1 EN
 PRESS RELEASE
Free
AVGR AVINGER INC

Avinger Closes $4.5 Million Equity Offering

Avinger Closes $4.5 Million Equity Offering REDWOOD CITY, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD) today announced the closing of an underwritten public offering of 3,813,559 shares of its common stock at a price of $1.18 per share, for total gross proceeds of approximately $4.5 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the Company has granted the underwriters a 45-day option to purchase up to ...

August 26, 2019 1 EN
 PRESS RELEASE
Free
AVGR AVINGER INC

Avinger Prices $4.5 Million Underwritten Public Offering of Common Sto...

Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock REDWOOD CITY, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $4.5 million before deducting underwriting discounts and commissions and other estimated offering expenses. The proposed offering equates to 3,813,559 shares of the Company’s common stock at a price of $1.18 per share. The Comp...

August 22, 2019 1 EN
 PRESS RELEASE
Free
AVGR AVINGER INC

Avinger Announces Proposed Underwritten Public Offering of Common Stoc...

Avinger Announces Proposed Underwritten Public Offering of Common Stock REDWOOD CITY, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the Company expects to grant the underwriter a 45-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover over-allotments, if any. The Company intends to ...

August 21, 2019 1 EN
 PRESS RELEASE
Free
AVGR AVINGER INC

Avinger Reports 26% Sequential Revenue Growth in Second Quarter 2019

Avinger Reports 26% Sequential Revenue Growth in Second Quarter 2019 Revenue Growth Fuels Strong Operating MetricsPantheris SV Limited Launch at Key U.S. Sites in July REDWOOD CITY, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported results for the quarter ended June 30, 2019. Second Quarter and Recent Highlights Increased revenue 26% from the first quart...

July 31, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch